Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026)
Fortrea Holdings (FTRE) posted Total Non-Current Liabilities of $2.1 billion for Q1 2026, little changed on a QoQ basis from $2.1 billion in Q4 2025, and down 4.78% year-over-year from $2.2 billion in Q1 2025.
Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Fortrea Holdings' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $2.1 billion for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 4.78% year-over-year to $2.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (down 4.78% YoY) and the FY2025 annual result came in at $2.1 billion, down 3.14% from the prior year.
- Total Non-Current Liabilities was $2.1 billion for Q1 2026 at Fortrea Holdings, roughly flat from $2.1 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.6 billion in Q1 2024 and bottomed at $923.6 million in Q4 2022.
- A 5-year average of $2.2 billion and a median of $2.2 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 180.03% — and 2024, when it fell 19.21%.
- Fortrea Holdings' Total Non-Current Liabilities stood at $923.6 million in 2022, then soared by 180.03% to $2.6 billion in 2023, then declined by 15.65% to $2.2 billion in 2024, then declined by 3.14% to $2.1 billion in 2025, then rose by 0.32% to $2.1 billion in 2026.
- Business Quant data shows FTRE's Total Non-Current Liabilities at $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 2.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.12 Bn |
| Dec 31, 2025 | 2.11 Bn |
| Sep 30, 2025 | 2.12 Bn |
| Jun 30, 2025 | 2.21 Bn |
| Mar 31, 2025 | 2.23 Bn |
| Dec 31, 2024 | 2.18 Bn |
| Sep 30, 2024 | 2.11 Bn |
| Jun 30, 2024 | 2.07 Bn |
| Mar 31, 2024 | 2.62 Bn |
| Dec 31, 2023 | 2.59 Bn |
| Sep 30, 2023 | 2.59 Bn |
| Jun 30, 2023 | 2.57 Bn |
| Dec 31, 2022 | 923.60 Mn |